How technology-driven patient communities transformed oncology adherence
A global pharma brand faced 50% therapy discontinuation within the first 8 weeks of an oral oncolytic. RxPx built a technology-driven patient community that changed the outcome — dramatically.
- 97% of patients retained in-app at 90 days vs. 31% industry average
- High engagement in side effect management content modules
- The app-based community model that drove daily engagement at scale
Trusted by leading life sciences companies
Proven at scale.
Why patients stopped treatment – and how RxPx changed that.
50% discontinuation within the first 8 weeks
A global pharma brand faced a critical adherence crisis with their oral oncolytic therapy. Clinical trials revealed that half of patients stopped treatment before it had a chance to work — driven by a combination of factors unique to this patient population.
Difficulty adhering to a twice-daily oral oncolytic regimen
Older patient population (average age 65–74) with lower digital literacy
Side effects driving patients to discontinue without clinical guidance
No existing mechanism to maintain patient engagement between appointments
A technology-driven patient community built around the patient’s life
RxPx launched an app-based patient community designed specifically for this therapy and patient population – combining peer support, education, and daily engagement tools to keep patients connected to their treatment journey.
App-based community designed for accessibility with an older patient cohort
Peer-to-peer support networks to normalise side effects and build resilience
Daily engagement touchpoints to reinforce adherence to the 2x daily regimen
Technology-driven insights to identify patients at risk of discontinuation
What you’ll walk away knowing.
The community model blueprint
The exact app-based community architecture RxPx built – and how it was designed for an older, less digitally native patient population.
Why traditional adherence programs fail
The specific failure modes of standard PSP approaches when applied to oncology – and why community changes the equation.
Retention outcomes vs. industry benchmarks
97% at 90 days, 70% at 1 year – the full results breakdown with industry average comparisons and what drove the difference.
How to apply this to your therapy area
A framework for evaluating where technology-driven patient communities can reduce discontinuation in your own program.
A look at what you’ll discover.
The question & the challenge
Can technology-driven patient communities truly drive engagement and adherence? The clinical context, the 50% discontinuation rate, and why standard approaches weren’t enough.
The RxPx community model
How RxPx designed and launched an app-based patient community built specifically for this therapy, this patient population, and the adherence challenges they faced.
Unlock full access
to case study.
Ready to see
the full results?
Find out exactly how RxPx drove 97% 90-day patient retention – and what it means for your therapy’s adherence program. Fill in your details below for instant access.
- 97% of patients retained in-app at 90 days vs. 31% industry average
- High engagement in side effect management content modules
- The app-based community model that drove daily engagement at scale
Why Most Therapies Fail After Approval (And No One Talks About It)
Every pharmaceutical launch is measured against ambitious commercial forecasts.
How Do We Embrace AI Without Compromising Ethics, Governance, and Trust?
How Do We Embrace AI Without Compromising Ethics, Governance, and Trust?
The Industry Shift Emerging From AXS26: From Fragmentation to Integration
At Asembia AXS26, one message surfaced repeatedly across conversations with manufacturers, specialty pharmacies, hubs, and patient support leaders: healthcare fragmentation is becoming impossible to ignore.